CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Prasugrel versus clopidogrel in patients with acute coronary syndromes Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison 'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk

Guideline2016 Nov;152(5):1243-1275.

JOURNAL:J Thorac Cardiovasc Surg. Article Link

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Levine GN, Bates ER, Bittl JA et al. Keywords: AHA; P2Y(12) inhibitor; Scientific Statements; acute coronary syndrome; aspirin; coronary artery disease; coronary stents; dual antiplatelet therapy (DAPT); focused update; stable ischemic heart disease

FULL TEXT PDF